Randomised clinical trial: Once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 8, 2013, Pages 767-775

  Flourie B ^a   Hagege H ^b   Tucat, G ^c   Maetz, D ^d   Hebuterne X ^e   Kuyvenhoven, J P ^c   Tan, T G ^f   Pierik, M J ^g   Masclee, A A M ^g   Dewit, O ^h   Probert, C S ⁱ   Aoucheta, D ^j  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^c CREGG ^*  (Netherlands)

^d Hazebrouck Medical Centre   (France)

^e UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

^f Medisch Centrum de Veluwe   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Hôpital Saint Luc   (Belgium)

ⁱ UNIVERSITY OF LIVERPOOL   (United Kingdom)

^j Ferring SAS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; CONTROLLED STUDY; DISEASE ACTIVITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROCTALGIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875229233     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12266     Document Type: Article

References (22)

1. Hanauer S,. Medical therapy for ulcerative colitis. Gastroenterology 2004; 126: 1582-92.
2. Travis S, Stange E, Lemann M, et al,. European-evidence-based consensus on the management of ulcerative colitis. J Crohns Colitis 2008; 2: 24-62.
3. Hussain F, Ajjan R, Kapur K, Moustafa M, et al,. Once versus divided dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther 2001; 15: 53-62.
4. Gandia P, Idier I, Houin G,. Is once-daily mesalazine equivalent to the currently used twice daily regimen? A study performed in 30 healthy individuals. J Clin Pharmacol 2007; 47: 334-42.
5. Kane S, Cohen R, Aikens J, et al,. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33.
6. Shale M, Riley S,. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18: 191-8.
7. Kane S,. Systemic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85.
8. Kamm M, Sandborn W, Gassull M, et al,. Once daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
9. Lichtenstein G, Kamm M, Boddu P, et al,. Effect of once or twice daily MMX mesalamine for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102.
10. Kruis W, Kiudelis G, Rácz I, et al,. Once daily versus three-times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut 2009; 58: 233-40.
11. Hanauer S, Schwartz J, Robinson M, et al,. Mesalazine capsules for treatment of active ulcerative colitis. Am J Gastroenterol 1993; 88: 1188-97.
12. Marteau P, Probert C, Lindgren S, et al,. Combined oral and enema treatment with Pentasa is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis. Gut 2005; 54: 960-5.
13. Sutherland L, Martin F, Greer S, et al,. 5-Aminosalicyclic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987; 92: 1894-8.
14. Rachmilewitz D,. Coated mesalazine (5-aminosalicyclic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 82-6.
15. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al,. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
16. Colombel J, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
17. Dave M, Loftus E,. Mucosal healing in inflammatory bowel disease-A true paradigm of success? Gastroenterol Hepatol 2012; 8: 29-38.
18. Bokemeyer B, Hommes D, Gill I, et al,. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J Crohns Colitis 2012; 6: 476-82.
19. Sandborn W, Kamm M, Lichtenstein G, et al,. MMX multi matrix system mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomised, double blind trials. Aliment Pharmacol Ther 2007; 26: 205-15.
20. Navarro F, Hanauer S,. Treatment of inflammatory bowel disease: safety and tolerability issues. Am J Gastroenterol 2003; 98 (Suppl. 12): S18-23.
21. Schreiber S, Hamling J, Zehnter E, et al,. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 1997; 40: 761-6.
22. Van Staa T, Travis S, Leufken S, et al,. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 2004; 126: 1733-9.